Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02906670 · ClinicalTrials.gov registry record · Phase 1
Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies
A Phase 1 study, sponsored by Symphogen A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02906670 is a Phase 1 study that was terminated before completion, run by Symphogen A/S. The registered enrollment target is 32 participants.
The verdict
NCT02906670, a Phase 1 study, was terminated before completion, sponsored by Symphogen A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is the first study to test Sym013 (Pan-HER) in humans. The primary purpose of this study is to see if Sym013 is safe and effective for patients with advanced epithelial malignancies without available therapeutic options.
Interventions
- DRUG Sym013
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-11-01 |
| Est. Completion | 2019-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02906670
The ClinicalTrials.gov registry entry for NCT02906670 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Symphogen A/S, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sym013 is the first listed.
NCT02906670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02906670 about?
NCT02906670 is a clinical study titled "Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies". This is the first study to test Sym013 (Pan-HER) in humans. The primary purpose of this study is to see if Sym013 is safe and effective for patients with advanced epithelial malignancies without available therapeutic options.
What is the current status of trial NCT02906670?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-11-01. Estimated completion is 2019-06.
What interventions are being tested in trial NCT02906670?
The interventions under investigation include: Sym013 (DRUG).
Who is sponsoring clinical trial NCT02906670?
This trial is sponsored by Symphogen A/S, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.